See also:
What is the most important information I should know about Levocarnitine (Maxnuron PG)?
This medicine is contraindicated in patients with anuria, inborn errors of amino acid metabolism, especially those involving branched chain amino acid metabolism such as Maple Syrup Urine Disease and Isovaleric Acidemia, or hypersensitivity to one or more amino acids present in the solution.
See also:
What is the most important information I should know about Pregabalin (Maxnuron PG)?
You may have thoughts about suicide while taking this medication. Your doctor will need to check you at regular visits. Do not miss any scheduled appointments.
Call your doctor at once if you have any new or worsening symptoms such as: mood or behavior changes, depression, anxiety, insomnia, or if you feel agitated, hostile, restless, hyperactive (mentally or physically), or have thoughts about suicide or hurting yourself.
If you are taking Pregabalin (Maxnuron PG) to prevent seizures, keep taking the medication even if you feel fine.
Do not stop using Pregabalin (Maxnuron PG) without first talking to your doctor, even if you feel fine. You may have increased seizures or withdrawal symptoms such as headache, sleep problems, nausea, and diarrhea. Ask your doctor how to avoid withdrawal symptoms when you stop using Pregabalin (Maxnuron PG).
Do not change your dose of Pregabalin (Maxnuron PG) without your doctor's advice. Tell your doctor if the medication does not seem to work as well in treating your condition.
Wear a medical alert tag or carry an ID card stating that you take Pregabalin (Maxnuron PG). Any medical care provider who treats you should know that you take seizure medication.
See also:
What are the possible side effects of Levocarnitine (Maxnuron PG)?
Applies to Levocarnitine (Maxnuron PG): capsule, powder, solution, tablet, wafer
In addition to its needed effects, some unwanted effects may be caused by Levocarnitine (Maxnuron PG) (the active ingredient contained in Levocarnitine (Maxnuron PG)). In the event that any of these side effects do occur, they may require medical attention.
Severity: ModerateIf any of the following side effects occur while taking Levocarnitine (Maxnuron PG), check with your doctor or nurse as soon as possible:
More common:
Some of the side effects that can occur with Levocarnitine (Maxnuron PG) may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:
More common:
See also:
What are the possible side effects of Methylcobalamin (Maxnuron PG)?
Tablet: Gastrointestinal: Symptoms eg, anorexia, nausea or diarrhea may occur infrequently.
Dermatological: Skin rash may occur rarely.
Others: Prolonged use of larger doses of Methylcobalamin (Maxnuron PG) is not recommended for patients whose occupation requires handling of mercury or its compounds.
Injection: Hypersensitivity: Use of Methylcobalamin (Maxnuron PG) should be discontinued if symptoms of hypersensitivity eg, eruptions, occur.
Others: Pain and induration may infrequently occur at the site of IM injection and headache, sweating or hot sensation may rarely occur.
See also:
What are the possible side effects of Pregabalin (Maxnuron PG)?
The Pregabalin (Maxnuron PG) clinical programme involved over 8900 patients who were exposed to Pregabalin (Maxnuron PG), of whom over 5600 were in double-blind placebo controlled trials. The most commonly reported adverse reactions were dizziness and somnolence. Adverse reactions were usually mild to moderate in intensity. In all controlled studies, the discontinuation rate due to adverse reactions was 12% for patients receiving Pregabalin (Maxnuron PG) and 5% for patients receiving placebo. The most common adverse reactions resulting in discontinuation from Pregabalin (Maxnuron PG) treatment groups were dizziness and somnolence.
In Table 2, all adverse reactions which occurred at an incidence greater than placebo and in more than one patient, are listed by class and frequency: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<l/10,000), not known (cannot be estimated from the available data).
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
The adverse reactions listed may also be associated with the underlying disease and/or concomitant medicinal products.
In the treatment of central neuropathic pain due to spinal cord injury the incidence of adverse reactions in general, CNS adverse reactions and especially somnolence was increased.
Additional reactions reported from post-marketing experience are included as Frequency not known in italics in the table below.
After discontinuation of short-term and long-term treatment with Pregabalin (Maxnuron PG) withdrawal symptoms have been observed in some patients. The following reactions have been mentioned: Insomnia, headache, nausea, anxiety, diarrhoea, flu syndrome, convulsions, nervousness, depression, pain, hyperhidrosis and dizziness, suggestive of physical dependence. The patient should be informed about this at the start of the treatment.
Concerning discontinuation of long-term treatment of Pregabalin (Maxnuron PG), data suggest that the incidence and severity of withdrawal symptoms may be dose-related.
Levocarnitine (Maxnuron PG)® (Levocarnitine (Maxnuron PG)) is indicated in the treatment of primary systemic carnitine deficiency. In the reported cases, the clinical presentation consisted of recurrent episodes of Reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. Associated symptoms included hypotonia, muscle weakness and failure to thrive. A diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation. In some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. Treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient.
Levocarnitine (Maxnuron PG)® (Levocarnitine (Maxnuron PG)) is also indicated for acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency.
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.Tab: Treatment of peripheral neuropathies. Inj: Megaloblastic anemia due to vit B12 deficiency, peripheral neuropathies.
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.Neuropathic Pain: Pregabalin (Maxnuron PG) is indicated for the treatment of neuropathic pain in adults, including neuropathic pain associated with spinal cord injury.
Epilepsy: Pregabalin (Maxnuron PG) is indicated as adjunctive therapy in adults with partial seizures, with or without secondary generalization.
Generalized Anxiety Disorder: Pregabalin (Maxnuron PG) is indicated for the treatment of Generalized Anxiety Disorder (GAD) in adults.
Fibromyalgia: Pregabalin (Maxnuron PG) is indicated for the management of fibromyalgia.
Levocarnitine (Maxnuron PG) is used to prevent and treat a lack of carnitine. It is used to prevent and treat this condition in patients with kidney disease on dialysis. It is given to people whose body cannot properly use carnitine from their diet. Lack of carnitine can lead to liver, heart, and muscle problems. Your doctor may treat lack of carnitine by prescribing Levocarnitine (Maxnuron PG) for you.
Carnitine comes in two forms. Levocarnitine (Maxnuron PG) (Levocarnitine (Maxnuron PG)) should not be confused with the D,Levocarnitine (Maxnuron PG) form (labeled as “vitamin B T”'). Only the L-form of carnitine is used by the body to treat serious carnitine deficiency. The D,L-form does not help the body use fat and can actually interfere with and cause a lack of Levocarnitine (Maxnuron PG).
Certain Levocarnitine (Maxnuron PG) products have been specifically approved by the U.S. Food and Drug Administration for medical use and are available only with your doctor's prescription.
Once a medicine has been approved for marketing for a certain use, experience may show that it is also useful for other medical problems. Although this use is not included in product labeling, Levocarnitine (Maxnuron PG) is used in certain patients with the following medical condition:
Methylcobalamin (Maxnuron PG) is a form of vitamin B12. Vitamin B12 is important for the brain and nerves, and for the production of red blood cells.
Methylcobalamin (Maxnuron PG) is used to treat vitamin B12 deficiency. Methylcobalamin (Maxnuron PG) is sometimes used in people with pernicious anemia, diabetes, and other conditions.
Methylcobalamin (Maxnuron PG) may also be used for purposes not listed in this medication guide.
Follow all directions on your medicine label and package. Tell each of your healthcare providers about all your medical conditions, allergies, and all medicines you use.
Pregabalin (Maxnuron PG) is used with other medicines to help control partial seizures (convulsions) in the treatment of epilepsy. Pregabalin (Maxnuron PG) will not cure epilepsy and will only work to control seizures for as long as you continue to take it.
Pregabalin (Maxnuron PG) is also used for postherpetic neuralgia (pain that occurs after shingles) and pain caused by nerve damage from diabetes or a spinal cord injury. It is used to treat a condition called fibromyalgia (muscle pain and stiffness).
Pregabalin (Maxnuron PG) works in the central nervous system (CNS) to control seizures and pain. It is an anticonvulsant and neuropathic pain agent.
Pregabalin (Maxnuron PG) is available only with your doctor's prescription.
Constituent of striated muscle and liver. It is used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias.
Each ampoule also contains D-mannitol 50 mg as an additive. pH 5.3-7.3. Osmotic Pressure (to physiological saline): Approximately 1.
Mecobalamin is α-(5,6-dimethylbenzimidazolyl)-Co-methyl-cobamide.
Molecular Formula: C63H91CoN13O14P.
Molecular Weight: 1344.4.
Mecobalamin occurs as a dark red, odorless and almost tasteless crystal or crystalline powder. It is sparingly soluble in water, methanol and ethanol and practically insoluble in acetone, ether and chloroform. Mecobalamin is hygroscopic and decomposes upon exposure to light.
Each capsule contains the following inactive ingredients: Mannitol, maize starch and talc.
Pregabalin (Maxnuron PG) is described chemically as (S)-3-(aminomethyl)-5-methylhexanoic acid. The molecular formula is C8H17NO2 and the molecular weight is 159.23.
Pregabalin (Maxnuron PG) is a white to off-white, crystalline solid with a pKa1 of 4.2 and a pKa2 of 10.6. It is freely soluble in water and both basic and acidic aqueous solutions. The log of the partition coefficient (n-octanol/0.05 M phosphate buffer) at pH 7.4 is -1.35.
Use Levocarnitine (Maxnuron PG) as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Levocarnitine (Maxnuron PG).
Use Pregabalin (Maxnuron PG) solution as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Pregabalin (Maxnuron PG) solution.
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.This medication is used to prevent and treat low blood levels of carnitine. Carnitine is a substance made in the body from meat and dairy products. It helps the body use certain chemicals (long-chain fatty acids) for energy and to keep you in good health. Low blood levels of carnitine may occur in people whose bodies cannot properly use carnitine from their diets, people on dialysis due to serious kidney disease, and people being treated with certain drugs (e.g., valproic acid, zidovudine). Carnitine levels that are too low can cause liver, heart, and muscle problems.
The injectable form of this drug is recommended if you have serious kidney disease (e.g., ESRD/dialysis) because high doses of the form taken by mouth may increase the risk of serious side effects. Consult your doctor or pharmacist for details.
How to use Levocarnitine (Maxnuron PG) intravenousThis medication is given into a vein by slow injection or through an IV, as directed by your doctor. The dosage is based on your weight, medical condition, and response to therapy.
If you are giving this medication to yourself at home, learn all preparation and usage instructions from your health care professional. Before using, check this product visually for particles or discoloration. If either is present, do not use the liquid. Learn how to store and discard medical supplies safely.
Inform your doctor if your condition persists or worsens.
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.Methylcobalamin (Maxnuron PG) is an active form of vitamin B12, which is used to treat anemia as well as nerve damage with numbness, tingling, pain in various neurological disorders.
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.Use: Labeled IndicationsFibromyalgia (immediate release only): Management of fibromyalgia
Neuropathic pain associated with diabetic peripheral neuropathy (immediate release and extended release): Management of neuropathic pain associated with diabetic peripheral neuropathy
Neuropathic pain associated with spinal cord injury (immediate release only): Management of neuropathic pain associated with spinal cord injury
Postherpetic neuralgia (immediate release and extended release): Management of postherpetic neuralgia
Seizures, focal (partial) onset (immediate release only): Adjunctive therapy in patients ≥1 month of age with focal onset (partial-onset) seizures
Off Label UsesCough, chronic refractory
Data from a limited number of patients in a controlled trial suggest that Pregabalin (Maxnuron PG) in combination with speech pathology therapy may be beneficial for the treatment of refractory chronic cough.
Based on the American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) position statement on menopause, the Endocrine Society guideline on the treatment of symptoms of menopause, and the North American Menopause Society (NAMS) position statement on nonhormonal management of menopause-associated vasomotor symptoms, Pregabalin (Maxnuron PG) is an effective and recommended alternative for the management of vasomotor symptoms associated with menopause in patients with contraindications to hormonal therapy or who prefer not to use hormonal therapy.
Adults: The recommended oral dosage for adults is 990 mg two or three times a day using the 330 mg tablets, depending on clinical response.
Infants and children: The recommended oral dosage for infants and children is between 50 and 100 mg/kg/day in divided doses, with a maximum of 3 g/day. Dosage should begin at 50 mg/kg/day. The exact dosage will depend on clinical response.
Monitoring should include periodic blood chemistries, vital signs, plasma carnitine concentrations and overall clinical condition.
Levocarnitine (Maxnuron PG)® (Levocarnitine (Maxnuron PG))Oral Solution and Levocarnitine (Maxnuron PG)® SF (Levocarnitine (Maxnuron PG)) Sugar-FreeOral SolutionFor oral use only. Not for parenteral use.
Adults: The recommended dosage of Levocarnitine (Maxnuron PG) is 1 to 3 g/day for a 50 kg subject, which is equivalent to 10 to 30 mL/day of Levocarnitine (Maxnuron PG)® (Levocarnitine (Maxnuron PG))
Oral Solution or Levocarnitine (Maxnuron PG)® SF (Levocarnitine (Maxnuron PG)) Sugar-FreeOral Solution. Higher doses should be administered only with caution and only where clinical and biochemical considerations make it seem likely that higher doses will be of benefit. Dosage should start at 1 g/day, (10 mL/day), and be increased slowly while assessing tolerance and therapeutic response. Monitoring should include periodic blood chemistries, vital signs, plasma carnitine concentrations, and overall clinical condition.
Infants and children: The recommended dosage of Levocarnitine (Maxnuron PG) is 50 to 100 mg/kg/day which is equivalent to 0.5 mL/kg/day Levocarnitine (Maxnuron PG)® (Levocarnitine (Maxnuron PG))
Oral Solution or Levocarnitine (Maxnuron PG)® SF (Levocarnitine (Maxnuron PG)) Sugar-FreeOral Solution. Higher doses should be administered only with caution and only where clinical and biochemical considerations make it seem likely that higher doses will be of benefit. Dosage should start at 50 mg/kg/day, and be increased slowly to a maximum of 3 g/day (30 mL/day) while assessing tolerance and therapeutic response. Monitoring should include periodic blood chemistries, vital signs, plasma carnitine concentrations, and overall clinical condition.
Levocarnitine (Maxnuron PG)® (Levocarnitine (Maxnuron PG))
Oral Solution or Levocarnitine (Maxnuron PG)® SF (Levocarnitine (Maxnuron PG)) Sugar-FreeOral Solution may be consumed alone or dissolved in drink or other liquid food. Doses should be spaced evenly throughout the day (every three or four hours) preferably during or following meals and should be consumed slowly in order to maximize tolerance.
How suppliedLevocarnitine (Maxnuron PG)® (Levocarnitine (Maxnuron PG)) Tablets are supplied as 330 mg tablets embossed with “Levocarnitine (Maxnuron PG) ST” in individual blisters, packaged in boxes of 90 (NDC 54482-144-07). Store at controlled room temperature (25°C). See USP. Levocarnitine (Maxnuron PG)® (Levocarnitine (Maxnuron PG)) Tablets are manufactured for Sigma-Tau Pharmaceuticals, Inc. by Sigma-Tau S.p. A., 00040 Pomezia (Rome), Italy.
Levocarnitine (Maxnuron PG)® (Levocarnitine (Maxnuron PG))
Oral SolutionNDCUSPOral Solution is manufactured for Sigma-Tau Pharmaceuticals, Inc. by: Hi-Tech Pharmacal Co., Inc. Amityville, NY 11701.
Levocarnitine (Maxnuron PG)® SF (Levocarnitine (Maxnuron PG)) Sugar-Free
Oral SolutionNDCUSPOral Solution is manufactured for Sigma-Tau Pharmaceuticals, Inc. by: Hi-Tech Pharmacal Co., Inc. Amityville, NY 11701.
Sigma-tau Pharmaceuticals, Inc., Gaithersburg, MD 20878. Revised: April 2015.
Tablet: Adults: Usual Daily Dose: 3 tabs, equivalent to a total of 1500 mcg of mecobalamin, administered orally in 3 divided doses. The dose should be adjusted according to age of patient and severity of symptoms.
Injection: Peripheral Neuropathies: The usual adult dosage is 1 amp, equivalent to 500 mcg of mecobalamin administered IM or IV 3 times a week. The dosage should be adjusted according to age of patient and severity of symptoms.
Megaloblastic Anemia: The usual adult dosage is 1 amp, equivalent to 500 mcg of mecobalamin administered IM or IV 3 times a week. After approximately 2 months of medication, the dose should be reduced to a single administration of 1 amp at 1- to 3-month intervals for maintenance therapy.
The dose range is 150 to 600 mg per day given in either two or three divided doses.
Epilepsy: Pregabalin (Maxnuron PG) treatment can be started with a dose of 150 mg per day given as two or three divided doses. Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after 1 week. The maximum dose of 600 mg per day may be achieved after an additional week.
Generalised Anxiety Disorder: The dose range is 150 to 600 mg per day given as two or three divided doses. The need for treatment should be reassessed regularly.
Pregabalin (Maxnuron PG) treatment can be started with a dose of 150 mg per day. Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after 1 week. Following an additional week, the dose may be increased to 450 mg per day. The maximum dose of 600 mg per day may be achieved after an additional week.
Discontinuation of Pregabalin (Maxnuron PG): In accordance with current clinical practice, if Pregabalin (Maxnuron PG) has to be discontinued, it is recommended this should be done gradually over a minimum of 1 week independent of the indication.
Patients with Renal Impairment: Pregabalin (Maxnuron PG) is eliminated from the systemic circulation primarily by renal excretion as unchanged drug. As Pregabalin (Maxnuron PG) clearance is directly proportional to creatinine clearance, dose reduction in patients with compromised renal function must be individualised according to creatinine clearance (CrCl), as indicated in Table 1 determined using the following formula.
Pregabalin (Maxnuron PG) is removed effectively from plasma by haemodialysis (50% of drug in 4 hours). For patients receiving haemodialysis, the Pregabalin (Maxnuron PG) daily dose should be adjusted based on renal function. In addition to the daily dose, a supplementary dose should be given immediately following every 4-hour haemodialysis treatment.
Patients with Hepatic Impairment: No dose adjustment is required for patients with hepatic impairment.
Children: The safety and efficacy of Pregabalin (Maxnuron PG) Sandoz in children below the age of 12 years and in adolescents (12-17 years of age) have not been established. No data are available.
Elderly (over 65 years of age): Elderly patients may require a dose reduction of Pregabalin (Maxnuron PG) due to a decreased renal function.
Administration: Pregabalin (Maxnuron PG) Sandoz may be taken with or without food.
Pregabalin (Maxnuron PG) Sandoz is for oral use only.
See also:
What other drugs will affect Levocarnitine (Maxnuron PG)?
Reports of INR increase with the use of warfarin have been observed. It is recommended that INR levels be monitored in patients on warfarin therapy after the initiation of treatment with Levocarnitine (Maxnuron PG) or after dose adjustments.
See also:
What other drugs will affect Pregabalin (Maxnuron PG)?
Since Pregabalin (Maxnuron PG) is predominantly excreted unchanged in the urine, undergoes negligible metabolism in humans (less than 2% of a dose recovered in urine as metabolites), and does not bind to plasma proteins, its pharmacokinetics are unlikely to be affected by other agents through metabolic interactions or protein binding displacement. In vitro and in vivo studies showed that Pregabalin (Maxnuron PG) is unlikely to be involved in significant pharmacokinetic drug interactions. Specifically, there are no pharmacokinetic interactions between Pregabalin (Maxnuron PG) and the following antiepileptic drugs: carbamazepine, valproic acid, lamotrigine, phenytoin, phenobarbital, and topiramate. Important pharmacokinetic interactions would also not be expected to occur between Pregabalin (Maxnuron PG) and commonly used antiepileptic drugs.
PharmacodynamicsMultiple oral doses of Pregabalin (Maxnuron PG) were co-administered with oxycodone, lorazepam, or ethanol. Although no pharmacokinetic interactions were seen, additive effects on cognitive and gross motor functioning were seen when Pregabalin (Maxnuron PG) was co-administered with these drugs. No clinically important effects on respiration were seen.
Drug Abuse And DependenceControlled SubstancePregabalin (Maxnuron PG) is a Schedule V controlled substance.
Pregabalin (Maxnuron PG) is not known to be active at receptor sites associated with drugs of abuse. As with any CNS active drug, carefully evaluate patients for history of drug abuse and observe them for signs of Pregabalin (Maxnuron PG) misuse or abuse (e.g., development of tolerance, dose escalation, drug-seeking behavior).
AbuseIn a study of recreational users (N=15) of sedative/hypnotic drugs, including alcohol, Pregabalin (Maxnuron PG) (450 mg, single dose) received subjective ratings of “good drug effect,” “high” and “liking” to a degree that was similar to diazepam (30 mg, single dose). In controlled clinical studies in over 5500 patients, 4 % of Pregabalin (Maxnuron PG)-treated patients and 1 % of placebo-treated patients overall reported euphoria as an adverse reaction, though in some patient populations studied, this reporting rate was higher and ranged from 1 to 12%.
DependenceIn clinical studies, following abrupt or rapid discontinuation of Pregabalin (Maxnuron PG), some patients reported symptoms including insomnia, nausea, headache or diarrhea, consistent with physical dependence. In the postmarketing experience, in addition to these reported symptoms there have also been reported cases of anxiety and hyperhidrosis.
